Open AccessPotential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus Infections
Author(s) -
Qiongqiong Angela Zhou,
Junko Kato-Weinstein,
Yingzhu Li,
Yi Deng,
Roger Granet,
L. Garner,
Cynthia Liu,
Dmitrii Polshakov,
Chris Gessner,
S. Craig Watkins
Publication year - 2020
Publication title -
acs pharmacology and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.271
H-Index - 10
ISSN - 2575-9108
DOI - 10.1021/acsptsci.0c00074
Subject(s) - repurposing , drug repositioning , covid-19 , pandemic , coronavirus , bioassay , drug discovery , furin , drug development , virology , biology , computational biology , drug , disease , medicine , pharmacology , bioinformatics , infectious disease (medical specialty) , genetics , pathology , ecology , biochemistry , enzyme
The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has led to several million confirmed cases and hundreds of thousands of deaths worldwide. To support the ongoing research and development of COVID-19 therapeutics, this report provides an overview of protein targets and corresponding potential drug candidates with bioassay and structure-activity relationship data found in the scientific literature and patents for COVID-19 or related virus infections. Highlighted are several sets of small molecules and biologics that act on specific targets, including 3CLpro, PLpro, RdRp, S-protein-ACE2 interaction, helicase/NTPase, TMPRSS2, and furin, which are involved in the viral life cycle or in other aspects of the disease pathophysiology. We hope this report will be valuable to the ongoing drug repurposing efforts and the discovery of new therapeutics with the potential for treating COVID-19.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom